Navigation Links
Convoy Therapeutics Announces the Relaunch of Their Interactive Website
Date:1/16/2013

Las Vegas (PRWEB) January 16, 2013

Convoy Therapeutics, a subsidiary of ACTUS Biotechnologies, is proud to announce the relaunching of their website. The revised website includes new information regarding the company's platform technology and development programs.

The interactive website provides a user-friendly platform for interested parties to gather information regarding Convoy Therapeutics’ innovative platform technology and its various uses in enabling the penetration of macromolecules and retention of small molecules in the skin for a wide variety of cosmetic and therapeutic uses.
“The revamped website offers comprehensive information regarding Convoy’s ground-breaking technology and how it can be applied in a variety of uses in cosmetic and therapeutic applications,” says Dr. Robert Davis, Chief Business Officer of Convoy Therapeutics. “Perhaps more importantly, it shows the incredible healing opportunities possible when combining other therapies with our skin-penetrating technologies.” Convoy Therapeutics’ main objective is to provide a platform for effective and efficient drug, cosmeceutical, or active delivery into the skin. “The website demonstrates the difference between the previous systems of skin delivery and Convoy’s technology,” adds Dr. Davis.

The newly designed website includes diagrams, videos, and slide presentations that visually demonstrate the Convoy technology penetrating the outer layers of the skin, delivering therapeutic macromolecules. Treatment areas include: dermatology, immunology, vaccinations, and cancer. The website also contains information regarding the company's development pipeline including: CY-102, a reformulated Cyclosporine for topical use in treating psoriasis currently in late stage development, and HA-102PH, a topical cosmetic preparation of hyaluronic acid for enhanced skin tone and hydration also in the later development stages.

The
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... York, NY (PRWEB) May 21, 2013 Bed ... And according to My Cleaning Products, many turn to chemical-based ... because of the health and environmental risks those solutions present, ... with Bed Bug Bully instead. , According to ... bed bugs as they used to be. It shared that ...
(Date:5/21/2013)... 2013 Inflamax scientists worked closely ... to design the study, which will provide critical ... models used in the study of allergy treatments, ... Challenge (NAC) models. Although both the models are ... date no direct comparison between the allergic responses ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... Scientists are using the engineering technology behind the ... models for the replacement of delicate and complex ... The researchers, combining engineering and plastic ... topological optimization to design an experimental 3-D structure ...
... IRVINE, Calif. , July 12 ... the development and commercialization of personalized DNA-based diagnostics ... completed license agreements with key Norwegian cancer researchers. ... promising genomic technologies with the intention of developing ...
... , July 12, 2010 Points to,Novel Pathway for Drug ... Abdominal Aortic Aneurysm, Heart Attack and,PAD , ... Scientists at deCODE genetics and academic ... and North America today,report the discovery of a common ...
Cached Biology Technology:High-performance engineering used to design facial bone replacements 2High-performance engineering used to design facial bone replacements 3OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 2OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 3OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 4deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 2deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 3deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 4
(Date:5/21/2013)... have developed a new method for delivering molecules ... the cell surface. The technique could find applications ... fields. , Bulk electroporation a technique used ... in the cell membrane that are caused by ... increasingly popular method of cell transfection. (Cell transfection ...
(Date:5/21/2013)... the University of Illinois at Chicago College of Medicine will ... fat -- its main energy source -- and how changes ... a new $2 million, 4-year grant from the National Heart, ... how it uses fuel for energy. These changes may play ... are different in men and women, says E. Douglas Lewandowski, ...
(Date:5/21/2013)... of biomass experts , Where? Copenhagen, ... 03-07 June 2013 , Why? ... assessment, market and policy developments, manufacturing and installation, drawing ... benefiting from its 2013 edition from a record of ... countries, more than 240 plenary and oral presentations, more ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Do men's and women's hearts burn fuel differently? 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4
... a gas they also produce naturally as a hormone, the result ... and fading in the case of flowers all of which ... plants with products available in the market today, such as EthylBloc ... for fruits and vegetables, that contain a compound that blocks ...
... mechanism of action of genes has been hampered by the ... is true for even the most common class of cancer-associated ... events in cells by phosphorylating and modulating the activity of ... efforts that up to a quarter of kinases may play ...
... TAMPA, Fla., May 1 Stinger Systems, Inc. ... today announced,that it had reached a settlement agreement ... Inc. said it settled the matter without admitting ... barring future,violations. Stinger Systems, Inc. also said that ...
Cached Biology News:A new idea for how anti-aging products delay ripening of fruit and wilting of flowers 2A new idea for how anti-aging products delay ripening of fruit and wilting of flowers 3
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
... a new technology for sensitive detection ... amounts of DNA (5). This process ... modify the DNA, followed by PCR ... distinguish methylated from unmethylated DNA. The ...
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. iEMS ... a one-cabinet model, allowing the ...
... atlantica Description: Beta-Agarase is useful in ... low-melting-temperature agarose. Beta-Agarase digests the agarose ... Friendly Properties: Heat Inactivation: 65C, 15 ... pH: 6.5 Purity: Tested for contaminating ...
Biology Products: